Australia to consider OTC switches for triptans

23 September 2019 - Deborah Wilkes

Premium

Australia's Advisory Committee on Medicines Scheduling (ACMS) will consider applications to switch two triptans – sumatriptan and zolmitriptan – from prescription to non-prescription status for treating migraine attacks. The committee will also consider reclassification proposals for the allergy remedy mometasone and caffeine.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: